---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-073986"
form_type: "8-K"
ticker: "ELAB"
cik: "0001840563"
company_name: "PMGC Holdings Inc."
filed_at: "2026-07-01T11:31:32+00:00"
generated_at: "2026-07-01T11:35:12.595657+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NorthStrive Biosciences reports positive Phase III results: 4 AI-selected compounds increase ANT1 expression up to 50%

## Summary
- Four AI-selected compounds (C1, C2, C3, C4) significantly increased ANT1 expression in human skeletal muscle cells.
- Strongest dose-dependent induction: C2 up to +50%, C4 up to +48%, C1 up to +46%, C3 +29% at highest dose.
- Yuva Biosciences recommended advancing the four candidates into a more mature muscle model for confirmatory testing.
- Results validate MitoNova AI platform's ability to identify biologically active small-molecule candidates.

## SEC filing metadata
- accession: 0001213900-26-073986
- form_type: 8-K
- ticker: ELAB
- cik: 0001840563
- company_name: PMGC Holdings Inc.
- filed_at: 2026-07-01T11:31:32+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840563/000121390026073986/0001213900-26-073986-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840563/000121390026073986/ea0296527-8k_pmgc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-073986
- JSON: https://secwatch.observer/filing/0001213900-26-073986.json
- Plain text: https://secwatch.observer/filing/0001213900-26-073986.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.